Paul Griffey, MD
Ophthalmology · Chesapeake, VANPI 1528027976
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,956 of the $9,657 with a category attached, or 82.4%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,469 and has fallen 62.0% since, to $1,317 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $30.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- Alcon$944
- Bausch & Lomb, A Division Of Bausch Health US, LLC$771
- Ocular Therapeutix, Inc.$606
- Notal Vision, Inc.$578
- plus $3K from 20 others
What the payments were for
- Travel & lodging$1,58316%
- Food & beverage$7,95682%
- Gifts$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 10 | $2,074 |
| AbbVie(2 entities) | 76 | $1,405 |
| Alcon | 33 | $944 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 33 | $771 |
| Ocular Therapeutix, Inc. | 22 | $606 |
| Notal Vision, Inc. | 1 | $578 |
| Sun Pharmaceutical Industries Inc. | 14 | $458 |
| Tarsus Pharmaceuticals, Inc. | 12 | $434 |
| Bausch & Lomb Americas Inc. | 17 | $335 |
| Novartis | 16 | $325 |
| Harrow Eye, LLC | 8 | $248 |
| Rxsight Inc | 3 | $209 |
| Aerie Pharmaceuticals, Inc. | 13 | $195 |
| Omeros Corporation | 9 | $168 |
| Kala Pharmaceuticals, Inc. | 9 | $157 |
| Rayner Intraocular Lenses Limited | 6 | $151 |
| Eyevance Pharmaceuticals LLC | 7 | $112 |
| Oyster Point Pharma, Inc. | 4 | $112 |
| Johnson & Johnson Vision Care, Inc. | 6 | $96 |
| Glaukos Corporation | 3 | $69 |
| Shire North American Group Inc | 3 | $52 |
| Thea Pharma Inc. | 2 | $47 |
| Dompe US, Inc. | 2 | $40 |
| Sight Sciences, Inc. | 2 | $33 |
| Eyepoint US, Inc. | 1 | $23 |
| NEW World Medical,inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,876
- Tecnis 3-piece IOL$1,876
- Tecnis Symfony IOL$1,876
- Tecnis Symfony Toric IOL$1,876
- DEXTENZA$159
- PanOptix$142
- CEQUA$132
- Centurion$128
- XDEMVY$120
- RXSIGHT CONTACT LENS$115
- RXSIGHT INJECTOR CARTRIDGE$115
- RXSIGHT INJECTOR HANDPIECE$115
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$115
- LIGHT ADJUSTABLE LENS (LAL)$115
- XEN$101
How this compares
$9,657 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 235 | $342,934 |
| XiidraLifitegrast | 101 | $143,250 |
| XdemvyLotilaner | 72 | $135,561 |
| Cyclosporine | 122 | $76,040 |
| LumiganBimatoprost | 139 | $73,524 |
| RhopressaNetarsudil Mesylate | 47 | $32,870 |
| Alphagan PBrimonidine Tartrate | 59 | $29,055 |
| CombiganBrimonidine Tartrate/Timolol | 51 | $27,479 |
| Brimonidine Tartrate | 255 | $26,716 |
| Latanoprost | 1,419 | $17,955 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 56 | $16,199 |
| Prednisolone Acetate | 591 | $15,415 |
| Travoprost | 51 | $11,087 |
| Ketorolac Tromethamine | 515 | $9,867 |
| Brinzolamide | 47 | $9,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,405 | $472,992484 claims |
| Bausch & Lomb Americas Inc.Xiidra | $335 | $143,250101 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $434 | $135,56172 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $195 | $41,74670 claims |
| AlconSimbrinza | $944 | $8,83029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Chesapeake
- Fredric GrossChesapeake$7K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.